A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open-label, Phase II trial investigating axitinib as a single-agent
maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients
with mCRC.